The Effect of Novel Polymorphisms in the Interleukin-6 (IL-6) Gene on IL-6 Transcription and Plasma IL-6 Levels, and an Association with Systemic-onset Juvenile Chronic Arthritis
Overview
Affiliations
During active disease, patients with systemic-onset juvenile chronic arthritis (S-JCA) demonstrate a rise and fall in serum interleukin-6 (IL-6) that parallels the classic quotidian fever. To investigate the possibility that this cytokine profile results from a difference in the control of IL-6 expression, we examined the 5' flanking region of the IL-6 gene for polymorphisms. A G/C polymorphism was detected at position -174. In a group of 383 healthy men and women from a general practice in North London, the frequency of the C allele was 0.403 (95% confidence interval 0.37-0.44). In comparison, 92 patients with S-JCA had a different overall genotype frequency, especially those with onset of disease at < 5 yr of age. This was mainly due to the statistically significant lower frequency of the CC genotype in this subgroup. When comparing constructs of the 5' flanking region (-550-+61 bp) in a luciferase reporter vector transiently transfected into HeLa cells, the -174C construct showed 0.624+/-0.15-fold lower expression than the -174G construct. After stimulation with LPS or IL-1, expression from the -174C construct did not significantly change after 24 h, whereas expression from the -174G construct increased by 2.35+/-0.10- and 3.60+/-0.26-fold, respectively, compared with the unstimulated level. Plasma levels of IL-6 were also measured in 102 of the healthy subjects, and the C allele was found to be associated with significantly lower levels of plasma IL-6. These results suggest that there is a genetically determined difference in the degree of the IL-6 response to stressful stimuli between individuals. The reduced frequency of the potentially protective CC genotype in young S-JCA patients may contribute to its pathogenesis. Similarly the individual's IL-6 genotype may be highly relevant in other conditions where IL-6 has been implicated, such as atherosclerosis.
Kacprzak B, Stanczak M, Surmacz J, Hagner-Derengowska M Orthop Rev (Pavia). 2025; 16:126041.
PMID: 39911284 PMC: 11798646. DOI: 10.52965/001c.126041.
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS).
Zhang W, Chen Y, Yao Z, Ouyang M, Sun M, Zou S Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861175 PMC: 11768236. DOI: 10.3390/ph18010114.
Errigo A, Dore M, Mocci G, Pes G Sci Rep. 2024; 14(1):30773.
PMID: 39730495 PMC: 11680967. DOI: 10.1038/s41598-024-80497-w.
Borzemska B, Cieszczyk P, Zekanowski C Cells. 2024; 13(22).
PMID: 39594578 PMC: 11593177. DOI: 10.3390/cells13221828.
Grippaudo C, Cafiero C, Grande N, Dassatti L, Palmirotta R, Castagnola R Bioengineering (Basel). 2024; 11(10).
PMID: 39451399 PMC: 11505315. DOI: 10.3390/bioengineering11101023.